Evaluating the Appropriateness of Existing Health-Related Quality of Life Measures in Lichen Planus
Tóm tắt
Lichen planus (LP) is an inflammatory skin disorder that can present in various forms across the body, including lesions on the skin (cutaneous LP [CLP]), scalp (lichen planopilaris [LPP]) and mucosal regions (mucosal LP [MLP]). Several existing patient-reported outcome measures (PROMs) were identified for potential use in LP clinical development programs. This study aimed to assess the content validity and psychometric measurement properties of the Dermatology Life Quality Index (DLQI), Epworth Sleepiness Scale (ESS), Scalpdex and Oral Lichen Planus Symptom Severity Measure (OLPSSM) in an LP population. Patients completed the PROs at various time points as part of an international Phase 2 clinical study in adults with MLP (n = 37), LPP (n = 37) and CLP (n = 37). Test-retest reliability, construct validity and sensitivity to change were assessed. In addition, qualitative cognitive debriefing interviews were conducted with adults with MLP (n = 20), LPP (n = 19) and CLP (n = 19) in the USA and Germany to examine the PROM content validity. The DLQI demonstrated adequate reliability and validity, although its ability to detect change was modest and most items were considered not relevant in qualitative interviews. The ESS had good reliability but limited evidence of validity and ability to detect change. Conceptual relevance varied according to the qualitative interview data. The Scalpdex was miscellaneous across domains, but the ‘Symptoms’ domain performed well overall. Overall, Scalpdex concepts were reported as relevant by most LPP patients interviewed. The OLPSSM demonstrated good psychometric properties and strong evidence of content validity. The psychometric and qualitative findings support the use of the OLPSSM and Scalpdex within specific LP subtypes but cautioned use of the DLQI. Administration of the ESS is not recommended in LP because of its poor psychometric performance. Given these limitations, further validation of non-specific disease measures is needed and/or the development of additional LP-specific PROMs. NCT04300296.
Tài liệu tham khảo
Le Cleach L, Chosidow O. Lichen planus. N Engl J Med. 2012;366(8):723–32.
Weston G, Payette M. Update on lichen planus and its clinical variants. Int J Women’s Dermatol. 2015;1(3):140–9.
Thandar Y, Maharajh R, Haffejee F, Mosam A. Treatment of cutaneous lichen planus (Part 1): a review of topical therapies and phototherapy. Cogent Med. 2019;6(1):1582467.
Gorouhi F, Davari P, Fazel N. Cutaneous and mucosal lichen planus: a comprehensive review of clinical subtypes, risk factors, diagnosis, and prognosis. Sci World J. 2014;2014: 742826.
Assouly P, Reygagne P. Lichen planopilaris: update on diagnosis and treatment. Semin Cutan Med Surg. 2009;28(1):3–10.
Ingafou M, Leao JC, Porter SR, Scully C. Oral lichen planus: a retrospective study of 690 British patients. Oral Dis. 2006;12(5):463–8.
Usatine RP, Tinitigan M. Diagnosis and treatment of lichen planus. Am Fam Physician. 2011;84(1):53–60.
Burke LB, Brennan MT, Ni Riordain R, Madsen LS. Novel oral lichen planus symptom severity measure for assessing patients’ daily symptom experience. Oral Dis. 2019;25(6):1564–72.
Cassol-Spanemberg J, Blanco-Carrión A, Rodríguez-de Rivera-Campillo ME, Estrugo-Devesa A, Jané-Salas E, López-López J. Cutaneous, genital and oral lichen planus: a descriptive study of 274 patients. Med Oral Patol Oral Cir Bucal. 2019;24(1):e1–7.
Lepe K, Nassereddin A, Salazar FJ. Lichen Planopilaris. StatPearls [Internet]. 2021. https://www.ncbi.nlm.nih.gov/books/NBK470325/.
Tadakamadla J, Kumar S, Lalloo R, Johnson NW. Qualitative analysis of the impact of oral potentially malignant disorders on daily life activities. PLoS ONE. 2017;12(4): e0175531.
Hsu D-Y, Chien W-C, Chung C-H, et al. Risk of anxiety and depression in patients with lichen planus: a nationwide population-based study. J Affect Disord. 2022;300:255–62.
Nassab A, Navabi N, Pour M, Charrosta N, Hashemipour M. Quality of life in patients with chronic oral mucosal conditions: a qualitative research. Pesqui Bras Odontopediatria Clín Integrada. 2021;21: e0092.
López-Jornet P, Camacho-Alonso F. Quality of life in patients with oral lichen planus. J Eval Clin Pract. 2010;16(1):111–3.
Nasimi M, Ahangari N, Lajevardi V, Mahmoudi H, Ghodsi SZ, Etesami I. Quality of life and mental health status in patients with lichen planopilaris based on dermatology life quality index and general health questionnaire-28 questionnaires. Int J Women’s Dermatol. 2020;6(5):399–403.
US Food and Drug Administration. Patient-Reported Outcome Measures: Use in medical product development to support labeling claims, Silver Spring, ML, 2009.
Finlay AY, Khan GK. Dermatology life quality index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–6.
Chen SC, Yeung J, Chren MM. Scalpdex: a quality-of-life instrument for scalp dermatitis. Arch Dermatol. 2002;138(6):803–7.
Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14(6):540–5.
Adamo D, Ruoppo E, Leuci S, Aria M, Amato M, Mignogna MD. Sleep disturbances, anxiety and depression in patients with oral lichen planus: a case–control study. J Eur Acad Dermatol Venereol. 2015;29(2):291–7.
Balcı DD, İnandı T. Dermatology life quality index scores in lichen planus: comparison of psoriasis and healthy controls. Turkderm-Turk Arch Dermatol Venereol. 2008;42(4):127–30.
Fiocco Z, Kupf S, Patzak L, et al. Quality of life and psychopathology in lichen planus: a neglected disease burden. Acta Derm Venereol. 2021;101(12):adv00619.
Sampogna F, Linder D, Piaserico S, et al. Quality of life assessment of patients with scalp dermatitis using the Italian version of the Scalpdex. Acta Derm Venereol. 2014;94(4):411–4.
Chernyshov PV. The evolution of quality of life assessment and use in dermatology. Dermatology. 2019;235(3):167–74.
Wiriyakijja P, Fedele S, Porter SR, Mercadante V, Ni RR. Patient-reported outcome measures in oral lichen planus: a comprehensive review of the literature with focus on psychometric properties and interpretability. J Oral Pathol Med. 2018;47(3):228–39.
Ni Riordain R, Hodgson T, Porter S, Fedele S. Validity and reliability of the chronic oral mucosal diseases questionnaire in a UK population. J Oral Pathol Med. 2016;45(8):613–6.
US Food and Drug Administration. Patient-Focused Drug Development: Methods to identify what is important to patients guidance for industry, food and drug administration staff, and other stakeholders. Silver Spring, MD. 2022.
US Food and Drug Administration. Patient-Focused Drug Development: Collecting comprehensive and representative input - guidance for industry, food and drug administration staff, and other stakeholders. In: (FDA) UFaDA, ed2020.
US Food and Drug Administration. Patient-Focused Drug Development: Methods to identify what is important to patients, guidance for industry, food and drug administration staff, and other stakeholders (Guidance 2). 2022.
US Food and Drug Administration. Patient-Focused Drug Development: Selecting, developing, or modifying fit-for-purpose clinical outcome assessments (draft guidance). In: Services USDoHaH, ed2022.
US Food and Drug Administration. Guidance for industry: Patient-Reported Outcome Measures: Use in medical product development to support labeling claims. 2009.
Willis GB. Cognitive interviewing: a tool for improving questionnaire design. Sage Publications; 2004.
ATLAS.ti Scientific Software Development GmbH [ATLAS.ti 22 Windows]. Retrieved from https://atlasti.com [computer program]. 2022.
Hsieh H, Shannon S. Three approaches to qualitative content analysis. Qual Health Res. 2005;15(9):1277–88.
Laga AC, Haefner HK, Granter SR. Noninfectious inflammatory disorders of the vulva. In: Diagnostic gynecologic and obstetric pathology. Elsevier; 2018. p. 22–52.
Koo TK, Li MY. A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med. 2016;15(2):155–63.
Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care. 1989;27(3 Suppl):S178-189.
Brennan MT, Madsen LS, Saunders DP, et al. Efficacy and safety of a novel mucoadhesive clobetasol patch for treatment of erosive oral lichen planus: a phase 2 randomized clinical trial. J Oral Pathol Med. 2022;51(1):86–97.
Nunnally J, Bernstein I. Psychometric theory. 3rd ed. New York: McGraw-Hill Inc.; 1994.
Cohen J. Statistical power analysis for the behavioral sciences. Routledge; 2013.
Hedges LV. Distribution theory for Glass’s estimator of effect size and related estimators. J Educ Stat. 1981;6(2):107–28.